Biolegend, 101328, APC/Cyanine7 anti-mouse CD16/32 Antibody, 100μg

CD16 is low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Sorted pre-B cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Red Laser (633 nm)
Application Notes: Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation1 and blocking of Fc-mediated reactions in functional studies2,4,23. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 µg per 106 cells in 100 µL volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered).
Application References(PubMed link indicates BioLegend citation): Personal communication (IP) Oliver AM, et al. 1999. Hybridoma 18:113. (Block) Brummel R and Lenert P. 2005. J. Immunol. 174:2429. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block) Clements JL, et al. 2006. J. Immunol. 177:905. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed Dutow P, et al. 2014. J Infect Dis. PubMed Fan Y, et al. 2014. J Exp Med. 211:313. PubMed Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed Takei S, et al. 2014. Vaccine. 32:3066. PubMed Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed Kimura T, et al. 2014. Int Immunol. 26:697. PubMed Everad A, et al. 2014. Nat Commun. 5:5648. PubMed Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block)
Product Citations: Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed Zhang D, et al. 2022. Cell Stem Cell. 29:232. PubMed Jabbar S, et al. 2022. Exp Hematol Oncol. 11:83. PubMed de Tymowski C et al. 2019. Cell reports. 27(3):762-775 . PubMed Bowers E, et al. 2018. Nat Med. 24:95. PubMed Thomas GE, et al. 2022. Nat Cell Biol. 24:872. PubMed Wei Q, et al. 2021. Nat Commun. 12:2522. PubMed Poh C, et al. 2014. Infect Immun . 82:4854. PubMed Li J, et al. 2019. JCI Insight. 5. PubMed Morales Torres C, et al. 2020. Nat Commun. 11:1792. PubMed Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed Carpenter RS, et al. 2020. Nat Commun. 3.029166667. PubMed Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed Amouzegar A, et al. 2017. Stem Cells. 10.1002/stem.2611. PubMed Lee SS, et al. 2022. Commun Biol. 5:654. PubMed Seneviratne AK, et al. 2019. Cell Stem Cell. 24:621. PubMed Cho K, et al. 2021. iScience. 24:103117. PubMed Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed Onai N, et al. 2020. Int J Mol Sci. :22. PubMed Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID: AB_1967102 (BioLegend Cat. No. 101327) AB_2104158 (BioLegend Cat. No. 101328)
Structure: Ig superfamily, 40-60 kD
Distribution: B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells
Function: Low affinity receptors for IgG
Ligand/Receptor: IgG
Cell Type: B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area: Immunology, Innate Immunity
Molecular Family: CD Molecules, Fc Receptors
Antigen References: 1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Unkeless JC. 1989. J. Clin. Invest. 83:355. 3. Qiu WQ, et al. 1990. Science 248:732.
Gene ID: 1413014131
UniProt: View information about CD16/32 on UniProt.org
Clone: 93
Regulatory Status: RUO
Other Names: Fcγ R III/II, Ly-17
Isotype: Rat IgG2a, λ